Ludy Shih is a Neurology physician affiliated with Boston University. OpenAlex indexes 101 publications with 2,981 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street
Shapiro 7, Suite B
Boston, MA 02118
Telephone
617-638-8456Provider last certified this registry record 14 Jun 2023.
Clinical trials
- Feasibility of Remote Measures and Assessments in Deep Brain Stimulation for Parkinson's Disease (FoRMA-DBS)
Sponsor: Boston Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year20255 payments
- Medtronic, Inc.Program year20254 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
93%Aromatic Amino Acid Decarboxylation Inhibitor39.5%Carbidopa-Levodopa75%Carbidopa-Levodopa Er22%Rytary4%Part D<11 patientsAnti-epileptic Agent12.3%Primidone100%Part D≥27 patients+ 13 more classes in this area
Cardiovascular
7%Beta blocker7%Propranolol Hcl64%Propranolol Hcl Er36%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Shifting From Active to Passive Monitoring of Alzheimer Disease: The State of the Research
Journal of the American Heart Association
2024 - Neutrophil‐to‐lymphocyte ratio and longitudinal cognitive performance in Parkinson's disease
Annals of Clinical and Translational Neurology
2024 - Comparing Cognitive Tests and Smartphone‐Based Assessment in 2 US Community‐Based Cohorts
Journal of the American Heart Association
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
Joseph Antin, MD
Boston University
George O'Connor, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”